Abnormal gene expression is an established cause of gastric cancer (GC) initiation and progression. By integrating bioinformatics and assay validations, we demonstrate that high expression of MYO5A, PLTP, or TPP1 is associated with tumor progress (1) and poor prognosis (2) in GC patients. These three genes may have potential to serve as predictive biomarkers for GC diagnosis and treatment.
展开▼
